NCT06234397View on ClinicalTrials.gov

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

245

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

August 31, 2027

Study Completion Date

January 31, 2028

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

BH3120

BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle

DRUG

pembrolizumab

Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle

Trial Locations (8)

13620

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

45219

RECRUITING

Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati

75230

RECRUITING

Mary Crowley Cancer Research, Dallas

78229

RECRUITING

Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cencer Center, San Antonio

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Severance Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT06234397 - Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter